{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:28:07Z","timestamp":1790742487093,"version":"4.1.0"},"reference-count":22,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"PHRC COVID","award":["PHRC COVID-19-20-0143, PHRC COVID-19-20-0029"],"award-info":[{"award-number":["PHRC COVID-19-20-0143, PHRC COVID-19-20-0029"]}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2021,12,23]]},"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Our objective was to determine whether anti-interleukin (IL)-6 receptors improve outcomes of critically ill patients with coronavirus disease 2019 (COVID-19) pneumonia. We report on two cohort-embedded, investigator-initiated, multicentre, open-label, Bayesian randomised controlled clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients were randomly assigned to receive either usual care (UC) or UC+tocilizumab (TCZ) 8\u2005mg\u00b7kg\n                      <jats:sup>\u22121<\/jats:sup>\n                      (TOCI-2 trial) or UC or UC+sarilumab (SARI) 200\u2005mg (SARI-2 trial), both intravenously on day 1 and, if clinically indicated, on day 3.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between 31 March and 20 April 2020, 97 patients were randomised in the TOCI-2 trial, to receive UC (n=46) or UC+TCZ (n=51). At day 14, numbers of patients who did not need noninvasive ventilation (NIV) or mechanical ventilation (MV) and were alive with TCZ or UC were similar (47%\n                      <jats:italic>versus<\/jats:italic>\n                      42%; median posterior hazard ratio (HR) 1.19, 90% credible interval (CrI) 0.71\u20132.04), with a posterior probability of HR &gt;1 of 71.4%. Between 27 March and 4 April 2020, 91 patients were randomised in the SARI-2 trial, to receive UC (n=41) or UC+SARI (n=50). At day 14, numbers of patients who did not need NIV or MV and were alive with SARI or UC were similar (38%\n                      <jats:italic>versus<\/jats:italic>\n                      33%; median posterior HR 1.05, 90% CrI 0.55\u20132.07), with a posterior probability of HR &gt;1 of 54.9%. Overall, the risk of death up to day 90 was: UC+TCZ 24%\n                      <jats:italic>versus<\/jats:italic>\n                      UC 30% (HR 0.67, 95% CI 0.30\u20131.49) and UC+SARI 29%\n                      <jats:italic>versus<\/jats:italic>\n                      UC 39% (HR 0.74, 95% CI 0.35\u20131.58). Both TCZ and SARI increased serious infectious events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In critically ill patients with COVID-19, anti-IL-6 receptors did not significantly increase the number of patients alive without any NIV or MV by day 14.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.02523-2021","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T12:28:15Z","timestamp":1643891295000},"page":"2102523","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":40,"title":["Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group"],"prefix":"10.1183","volume":"60","author":[{"given":"Olivier","family":"Hermine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5277-4679","authenticated-orcid":false,"given":"Raphael","family":"Porcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Resche-Rigon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6062-5905","authenticated-orcid":false,"given":"Pierre-Louis","family":"Tharaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ravaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"2024102102494461000_60.2.2102523.1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa199"},{"key":"2024102102494461000_60.2.2102523.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"2024102102494461000_60.2.2102523.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30211-7"},{"key":"2024102102494461000_60.2.2102523.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002032"},{"key":"2024102102494461000_60.2.2102523.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"2024102102494461000_60.2.2102523.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436"},{"key":"2024102102494461000_60.2.2102523.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2021.06.018"},{"key":"2024102102494461000_60.2.2102523.8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/jmv.26085","article-title":"Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis","volume":"93","author":"Zhu","year":"2020","journal-title":"J Med Virol"},{"key":"2024102102494461000_60.2.2102523.9","doi-asserted-by":"publisher","DOI":"10.1038\/S41591-020-1051-9"},{"key":"2024102102494461000_60.2.2102523.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.06.001"},{"key":"2024102102494461000_60.2.2102523.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41385-021-00464-w"},{"key":"2024102102494461000_60.2.2102523.12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial","volume":"181","author":"Hermine","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2024102102494461000_60.2.2102523.13","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/jamainternmed.2021.2209","article-title":"Effectiveness of tocilizumab in patients hospitalized with COVID-19: a follow-up of the CORIMUNO-TOCI-1 randomized clinical trial","volume":"181","author":"Mariette","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2024102102494461000_60.2.2102523.14","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2665-9913(21)00315-5","article-title":"Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): an open-label randomised controlled trial","volume":"4","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2024102102494461000_60.2.2102523.15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c1066"},{"key":"2024102102494461000_60.2.2102523.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30483-7"},{"key":"2024102102494461000_60.2.2102523.17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jamainternmed.2020.6252","article-title":"Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19","volume":"181","author":"Gupta","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2024102102494461000_60.2.2102523.18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.11330"},{"key":"2024102102494461000_60.2.2102523.19","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2213-2600(21)00099-0","article-title":"Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Lescure","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024102102494461000_60.2.2102523.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100433"},{"key":"2024102102494461000_60.2.2102523.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00676-0"},{"key":"2024102102494461000_60.2.2102523.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2304"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.02523-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T02:22:46Z","timestamp":1740363766000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.02523-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,8,10]]},"published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1183\/13993003.02523-2021"],"URL":"https:\/\/doi.org\/10.1183\/13993003.02523-2021","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]}}}